Mereo BioPharma Group plc (NASDAQ:MREO)’s traded shares stood at 1.32 million during the last session. At the close of trading, the stock’s price was $2.22, to imply an increase of 2.30% or $0.05 in intraday trading. The MREO share’s 52-week high remains $4.71, putting it -112.16% down since that peak but still an impressive 14.41% since price per share fell to its 52-week low of $1.90. The company has a valuation of $224.58M, with an average of 1.22 million shares in intraday trading volume over the past 10 days and average of 1.05 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Mereo BioPharma Group plc (MREO), translating to a mean rating of 1.30. Of 1 analyst(s) looking at the stock, 0 analyst(s) give MREO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $0.
Mereo BioPharma Group plc (NASDAQ:MREO) trade information
After registering a 2.30% upside in the last session, Mereo BioPharma Group plc (MREO) has traded red over the past five days. The stock hit a weekly high of 2.59 this Thursday, 10/07/21, jumping 2.30% in its intraday price action. The 5-day price performance for the stock is -8.26%, and -17.78% over 30 days. With these gigs, the year-to-date price performance is -37.99%. Short interest in Mereo BioPharma Group plc (NASDAQ:MREO) saw shorts transact 7.52 million shares and set a 10.33 days time to cover.
Analysts on Wall Street suggest a consensus price target of $10.00, implying an increase of 77.8% to the stock’s current value. The extremes give us $10.00 and $10.00 for target low and target high price respectively. As such, MREO has been trading -350.45% off suggested target high and -350.45% from its likely low.
Mereo BioPharma Group plc (MREO) estimates and forecasts
Looking at statistics comparing Mereo BioPharma Group plc share performance against respective industry, we note that the company has outperformed competitors. Mereo BioPharma Group plc (MREO) shares are -45.59% down over the last 6 months, with its year-to-date growth rate higher than industry average at 83.44% against 7.00%.
Mereo BioPharma Group plc has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Mereo BioPharma Group plc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Mereo BioPharma Group plc (NASDAQ:MREO)’s Major holders
Mereo BioPharma Group plc insiders hold 0.24% of total outstanding shares, with institutional holders owning 84.71% of the shares at 84.92% float percentage. In total, 84.71% institutions holds shares in the company, led by Orbimed Advisors LLC. As of Jun 29, 2021, the company held over 17.26 million shares (or 15.96% of shares), all amounting to roughly $54.73 million.
The next major institution holding the largest number of shares is Point72 Asset Management, L.P. with 10.11 million shares, or about 9.35% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $32.04 million.
We also have Tekla Healthcare Investors and Primecap Odyssey Aggressive Growth Fund as the top two Mutual Funds with the largest holdings of the Mereo BioPharma Group plc (MREO) shares. Going by data provided on Jun 29, 2021, Tekla Healthcare Investors holds roughly 0.72 million shares. This is just over 0.66% of the total shares, with a market valuation of $2.27 million. Data from the same date shows that the other fund manager holds a little less at 0.38 million, or 0.36% of the shares, all valued at about 0.99 million.